Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The prevalence of congestive heart failure (CHF) in Canada is high, representing one of the
health care system's most expensive diagnoses. Despite major advances in medicine, the
mortality and morbidity from CHF remains great. Currently, magnetic resonance imaging (MRI)
is used for non-invasive imaging of the cardiovascular system to enable the structure and
anatomy of the organ to be visualized. However, current MRI methods have limitations when
assessing and aiding in the management of CHF. A new imaging method has recently been
developed that is showing great promise as a tool in the management of patients with CHF.
Rapid imaging of biochemical reactions within myocytes using MRI has recently become possible
through the use of the Dynamic Nuclear Polarization (DNP) and dissolution method.
DNP-dissolution results in an intravenous contrast agent that is "hyperpolarized", producing
a magnetic signal that is enhanced by up to 100,000 fold. The particular agent is carbon-13
labelled pyruvate. In this study, we demonstrate the first 13C-metabolic images of the human
heart, along with the required hardware and data acquisition methods.